Study title: A single-centre, randomised, double-blind, placebo-controlled pilot study of cross-over design testing nifedipine in patients with cystic fibrosis.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Cardiovascular Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: NIFEPIDINE | |||||
| ATC code: C08CA05 | |||||
| Document link: Bayer Pharma_Nifedipine_1123_study_synopsis.pdf | |||||
| Document date: 2011-09-07 | |||||
| Study number: 1123 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |